Current approaches to the adoptive immunotherapy of cancer.
Current approaches to the adoptive immunotherapy of cancer.
复制标题
目前癌症过继免疫疗法的方法。
DOI：
--
复制
发表时间：
1988
影响因子：
--
通讯作者：
S. Rosenberg
中科院分区：
文献类型：
--
作者：
J. C. Yang;S. Rosenberg
白细胞介素2提供了从荷瘤宿主产生活化淋巴细胞的方法，其显示体外抗肿瘤活性。这些细胞可以来源于普遍存在的空细胞前体群体，在IL 2中培养后表现出几乎所有肿瘤的混杂溶解（即，LAK细胞）或来自浸润肿瘤的T细胞前体群体，并显示出对活化后自体肿瘤裂解的一些相对特异性（即，TIL）。当用于小鼠细胞过继免疫治疗模型时，LAK细胞和TIL都能够对已建立的微转移性肿瘤显示出显著的抗肿瘤作用。LAK细胞随后被用于针对转移性人类肿瘤的过继免疫治疗，并且在有限数量的病例中能够介导不同组织学的晚期癌症的消退。过继性免疫疗法作为人类肿瘤标准疗法的作用将取决于方法学的改进以及提高疗效和降低毒性的进展。TIL在这些领域可能具有理论优势，目前正在努力评估这些新的抗肿瘤试剂在癌症患者治疗中的作用。
Interleukin 2 has provided the means of generating activated lymphocytes from the tumor-bearing host which show in vitro anti-tumor activity. These cells can be derived either from a ubiquitous null cell precursor population, exhibiting promiscuous lysis of nearly all tumors after culture in IL2 (ie. the LAK cell) or from a T cell precursor population infiltrating tumors and showing some relative specificity for lysis of the autologous tumor following activation (ie. TIL). When utilized in murine cellular adoptive immunotherapy models, both LAK cells and TIL are able to display marked anti-tumor effects against established micrometastatic tumor. LAK cells have been subsequently employed in adoptive immunotherapy against metastatic human tumors and in a limited number of cases have been able to mediate the regression of advanced cancers of differing histologies. The role of adoptive immunotherapy as standard therapy of human tumors will depend on refinement of the methodology and progress toward increased efficacy and reduced toxicity. TIL may possess theoretical advantages in these areas and efforts are currently proceeding to evaluate these new anti-tumor reagents in the the treatment of patients with cancer.